RGNX - REGENXBIO Inc.
| Previous Close | 45.29 |
| Open | 45.84 |
| Bid | 45.25 x 900 |
| Ask | 60.00 x 800 |
| Day's Range | 45.50 - 47.47 |
| 52 Week Range | 23.25 - 85.10 |
| Volume | 539,946 |
| Avg. Volume | 494,250 |
| Market Cap | 1.689B |
| Beta (3Y Monthly) | 1.08 |
| PE Ratio (TTM) | 20.51 |
| EPS (TTM) | 2.30 |
| Earnings Date | Mar 4, 2019 - Mar 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.07 |
- PR Newswire•17 days ago
REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- PR Newswire•17 days ago
REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update
REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today provided a year-end 2018 corporate update. In 2018, we received over $200 million from our partners, and we believe our strong financial position will enable us to execute on our corporate goals throughout 2019," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.
Market Realist•last monthWhy Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.
- Insider Monkey•last month
Is Regenxbio Inc (RGNX) A Good Stock To Buy?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
- American City Business Journals•2 months ago
This Rockville biotech is getting some help from Maryland, MoCo for its new HQ
Rockville-based RegenxBio Inc. (NASDAQ: RGNX) locked in a new headquarters site about a month ago. Now more details have emerged about financial incentives it is receiving from Maryland and Montgomery County. The Maryland Department of Commerce approved a $700,000 conditional loan through Advantage Maryland, formerly the Maryland Economic Development Assistance Authority and Fund, and Montgomery County approved a $100,000 conditional grant, and will help expedite the permitting process for the new location, according to a release.
Market Realist•2 months agoArrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date. On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.
- Business Wire•2 months ago
Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
Rocket Pharmaceuticals, Inc. (RCKT), a leading U.S.-based multi-platform gene therapy company, and REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO’s NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vectors for the treatment of Danon disease.
- PR Newswire•2 months ago
REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
ROCKVILLE, Md. and NEW YORK, Nov. 26, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Rocket Pharmaceuticals, Inc. (RCKT), a leading U.S.-based multi-platform gene therapy company, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO's NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vectors for the treatment of Danon disease.
Market Realist•2 months agoAnalyzing Editas Medicine’s Operational Performance
Editas Medicine (EDIT) incurred general and administrative expenses of $13.33 million in the third quarter—compared to $12.63 million in the third quarter of 2017. The increase was due to higher stock-based compensation and employee-related expenses during this period.
Market Realist•2 months agoEditas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
Market Realist•2 months agoWho’s Eyeing Editas Medicine?
Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.
- GlobeNewswire•2 months ago
DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.
- PR Newswire•2 months ago
FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease
ROCKVILLE, Md., Nov. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to RGX-181, a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene. "We believe RGX-181 has the potential to correct the underlying genetic condition, halt progression and address many of the serious and life-threatening symptoms of CLN2 disease," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Regenxbio Inc Earnings Call
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Associated Press•2 months ago
Regenxbio: 3Q Earnings Snapshot
The Rockville, Maryland-based company said it had a loss of 56 cents per share. The biotechnology company posted revenue of $5.3 million in the period. Regenxbio shares have more than doubled since the ...
- American City Business Journals•2 months ago
This Rockville biotech is expanding to a new HQ. Here are the details.
The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.
- PR Newswire•2 months ago
Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facility
PASADENA, Calif. , Nov. 7, 2018 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation ...
- PR Newswire•2 months ago
REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
- Announces first subject dosed in RGX-121 Phase I/II clinical trial for MPS II - Completed Cohort 4 dosing in RGX-314 Phase I clinical trial for wet AMD - Sustained RGX-314 protein levels at six months ...
- PR Newswire•2 months ago
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- PR Newswire•3 months ago
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
ROCKVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1 (CLN1 Disease), and Juvenile Batten Disease, also known as neuronal ceroid lipofuscinosis type 3 (CLN3 Disease).
- PR Newswire•3 months ago
REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Oct. 31, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•3 months ago
ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?
ANIK vs. RGNX: Which Stock Is the Better Value Option?
- PR Newswire•3 months ago
REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
ROCKVILLE, Md., Oct. 26, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced updated results from the ongoing Phase I study of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). The results were presented by Jeffrey Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston, and primary investigator for the trial, at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2018 Annual Meeting. In August 2018, REGENXBIO presented an interim trial update on the first three dose cohorts, as of July 27, 2018, demonstrating that RGX-314 was well-tolerated and showed dose-dependent protein expression levels and dose-dependent reductions in anti-vascular endothelial growth factor (anti-VEGF) injections, along with maintenance of central retinal thickness and vision.
